Considerable developments in prostate cancer in 2013 have emerged from the imaging field. Hyperpolarized 13 C-MRI can monitor metabolic activity to identify high-grade disease and treatment response, and novel PET radiotracers might identify distinct subsets of patients with advanced disease. These examples highlight the progress made at all stages of care.
midurethral sling surgery for female SUI were reported in late 2013. 6 The primary outcome measure was patientreported improvement, with secondary outcomes including subjec tive and objective cure. The study allowed crossover between arms, which was revealing in that 49% of women in the physiotherapy group crossed over to surgery, whereas 11.2% of patients in the surgery group crossed over to physiotherapy. Not unexpectedly, the improvement and cure rates were signifi cantly higher in the surgery group than in the physiotherapy group. In the sling group, 91% of patients reported improvement, with 85% subjectively and 76% objectively cured; for physiotherapy, 64% of patients reported improvement, with 53% subjectively and 59% objectively cured. These results provide a useful tool for counselling patients on the response rates to these SUI treatments.
This study also gives insight into complica tions arising from mesh suburethral slings. The rate of adverse events in those who received physiotherapy only (no crossover) was essentially zero. By contrast, in the sling surgery group, adverse effects and compli cations included bladder perforation (2.8%), vaginal mesh exposure (3.7%), reoperation for exposure of the mesh (2.3%), reoper ation to loosen the sling (0.5%) and de novo OAB (6%). These complication rates are similar to other published series and high light the safety of synthetic mesh use in sub urethral slings, in contrast to the contro versial use of transvaginal synthetic mesh for POP, which uses larger mesh implants.
Secondary analysis from the ValUE trial, 7 which showed that outcomes for women undergoing treatment for SUI did not change with the addition of preoperative uro dynamic evaluation, were also reported in 2013 by the Urinary Incontinence Treatment Network. 8 Researchers showed that uro dynamic assess ment significantly changed the clinical diag nosis and the likelihood of additional treatment for urgency inconti nence postoperatively, but did not change global treatment plan or decisionmaking to modify or cancel surgery. This finding pro vides further support for current guidelines that patients with demonstrable SUI on office evaluation can undergo surgical treatment without urodynamics. 9 Finally, longterm data for the use of abdominal sacrocolpopexy as a surgical treatment for POP were presented in a study by the Pelvic Floor Disorders Network. 10 The study reported outcomes after a median of 7 years for participants in the CARE (Colpopexy and Urinary Reduction Efforts) trial. The 2year CARE trial initially com pared sacrocolpopexy with and without concomitant Burch urethropexy for SUI and POP outcomes. The latest report used data from the extended CARE trial for 126 women (59% of the original cohort). Failure was defined as symptomatic or anato mical POP failure requiring retreatment, selfreported vaginal bulge or POP quantifi cation evalu ation demonstrating recurrent anatomical prolapse. The estimated composite prob ability of failure of abdominal sacrocolpo pexy at 7 years was 0.48 and 0.34 for patients with and without concomitant urethro pexy, respectively-failure rates that increased over time compared with 5year POP failure (probability of 0.39 and 0.29 for patients with and without concomitant urethropexy, respectively), indicating that both early and late failures are common. Additionally, the authors reported a symptomatic and examdetected mesh and suture exposure rate of 9.9% for this population, which also increased over time and is higher than previ ously reported for trans abdominally placed mesh, indicating that close followup for signs and symptoms of mesh or suture expo sure is as important in this group as it is in patients with transvaginal mesh.
Several advances in the treatment of OAB in men and women were actively studied and widely used clinically in 2013 after the pub lication of key clinical trials, including mira begron treatment. Outcomes for treatments for SUI and POP were scrutinized for oppor tunities for improvement. Looking forward, studies in 2014 are likely to investigate how to best integrate these results into clinical guidelines and algorithms and to promote i nnovation where outcomes can be improved.
Alongside advances in drug development, 2013 has arguably been the year of imag ing in prostate cancer. Emerging imaging modalities are now being applied at all points in the disease process-including at initial diagnosis, during active surveillance of 1 examined 95 men with suspected prostate cancer on the basis of a suspicious lesion detected on mpMRI. MRItargeted biopsies in these men yielded higher rates of cancer, including clinically significant prostate cancer defined by any Gleason ≥4 pattern, than a standard sys tematic 12core ultrasonographyguided biopsy, particularly in the anterior region of the gland. 1 Although validation is required in a broader unenriched patient population, as is longterm follow up data to accurately determine falsenegative biopsy rate, the use of prebiopsy mpMRI might eventu ally be incorporated into standard diagnos tic algorithms to increase the sensiti vity of this approach to detect clinically s ignificant highgrade prostate cancer.
For patients with an established prostate cancer diagnosis, avoiding over treatment of lowrisk, clinically insignificant localized prostate cancer has spurred the develop ment of active surveillance strat egies that incorporate serial biopsies and PSA measure ment. However, despite gains in popularity, concerns regarding the risk of undetected highgrade disease often prompt patients to opt for definitive treatment in the absence of objective evidence of disease up staging. Novel genomic predictive biomarkers can improve upon stand ard clin ical risk stratifi cation criteria, but are still prone to sampling error related to the biopsy pro cedure.
2 Given this limitation, mpMRI might have clinical utility in expanding the number of patients with confirmed lowrisk disease who would be appropriate candi dates for active surveillance. At the same time, the technique can enhance the ability to detect occult highgrade disease and identify patients who should receive defini tive local therapy. One review published in 2013 included 133 patients who underwent mpMRI a median of 60 days before radical prostate ctomy. 3 The researchers showed that mpMRI was better than common clini cal scoring systems (D' Amico, Epstein and UCSF-CAPRA) at correctly classifying patients as appropriate for treatment versus active surveillance on the basis of domi nant tumour volume, predominant Gleason pattern and extra capsular or seminal vesicle invasion. Only one of the 13 patients with highrisk pathological disease was classi fied as low risk on mpMRI. Although prospec tive valid ation is required using a standard ized MRI scoring system, and integra tion of recently validated genomicbased prediction scores is essential, mpMRI has the potential to play a key part in improving the accu racy of selecting a ppropriate candidates for active surveillance.
A new molecular imaging MRI technique, hyperpolarized 13 CMRI, which relies on the detection of carbon nuclei rather than protons, also has the potential to improve cancer diagnosis, risk stratification and, in particular, the monitoring of treatment response. 13 CMRI provides enhanced spatial and temporal resolution compared with 1 HMRSI and can be used in the noninvasive realtime assessment of metabolic activity to image cancer. For example, 13 Cpyruvate-a metabolite involved in the synthesis of lactate via aerobic glycolysis, a pathway upregulated in cancerous cells by way of the Warburg effect-can be used across a spectrum of malignancies that includes prostate cancer. In the first ever phase I study of metabolic MRI using 13 Cpyruvate reported in 2013, 31 treatmentnaive patients with biopsy proven localized prostate cancer were enrolled, the majority of whom had Gleason 3 + 3 disease. 4 Patients were injected with the 13 Clabelled pyruvate, shortly after which its conversion to lactate could be observed in prostate tumours and, in some cases, in regions of cancer that were not detected by conventional MRI. Although targeted biop sies were not mandatory in the study design, one patient with previously diagnosed Gleason 3 + 3 prostate adenocarcinoma with unilateral disease on MRI was shown to have bilateral elevations in the ratio of lactate to pyruvate on 13 CMRI. This patient's tumour was sub sequently upstaged and upgraded, to bilateral Gleason 3 + 4 cancer, on directed 13 CMRIguided biopsy. 13 CMRI of hyper polarized pyruvate might, therefore, have a role in detecting occult highgrade disease to aid in treatment selection and prognostic ation of patients with localized prostate cancer. Future patient studies are needed to define the utility of this imaging modality in assessing treatment response, and pro spective studies will be needed to correlate imaging findings with histological grade at the time of radical prostatectomy.
Approximately 25-35% of patients who initially respond to definitive local therapy will experience biochemical relapse. PSA doublin g time, Gleason grade at time of diagnosis and time interval from definitive therapy to incidence of relapse are used to predict patterns of recurrence (loco regional versus distant), but there is considerable overlap between these clinical metrics. PET based imaging might offer a more sensitive
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Key advances
■ Multiparametric MRI (mpMRI)-targeted biopsies yielded higher rates of prostate cancer detection, including clinically significant (Gleason ≥4) disease, than standard 12-core guided biopsy, demonstrating its potential for improved risk stratification 1 ■ mpMRI performed better than clinical assessment scoring systems in predicting which patients were appropriate active surveillance candidates ■ New PET-based molecular imaging approaches have promise as biomarkers in advancedstage prostate cancer, distinguishing between androgen-receptor-dependent 8, 9 and treatmentemergent neuroendocrine prostate cancer method of detecting regional disease, distant spread of disease or both than conventional crosssectional imaging and clinical para meters. A 2013 systematic review and meta analysis of 19 independent studies high lighted the potential benefit of 11 Ccholine PET imaging, demonstrating a favour able sensitivity and specificity for detecting recurrent cancer: sensitivity and specific ity for detection in the prostatic fossa were 75.4% and 82% and for lymph node metas tases were 100% and 81.8%, respectively. FNaF PET has demonstrated increased sensitivity for detecting distant osseous metastases compared with conven tional 99 Tc bone scanning, including patients with biochemically relapsed disease who are at elevated risk of metastatic disease owing to a rapid rise in serum PSA level. 6 Androgen deprivation therapy is the stand ard of care for patients with recur rent or metastatic disease, but all patients eventual ly develop castrationresistant pros tate cancer (CRPC). Considerable molecu lar heterogeneity underlies the biology of CRPC, with continued reliance on andro gen receptor (AR)mediated signalling that frequently gives rise to ARindependent, cMYCdriven neuroendocrine prostate cancer (NEPC) as a treatmentemergent adaptive response. 7 Although no currently available bio markers are able to readily identify and predict subsets of patients who are most likely to respond to contin ued ARdirected therapy, new PETbased molecular imaging approaches might offer a suitable alternative and have the potential to accurately distinguish ARdependent pros tate cancer from treatment emergent NEPC. Indeed, 18 Ffluoro5αdihydrotestosterone ( 18 FFDHT)PET was used as a pharmacody namic biomarker of AR ligand binding in the early phase clinical trials of the s econdgen eration AR antagonists ARN509 and enzalu tamide, and helped guide the recom mended phase II dose selection of these two agents. 8 Emerging molecular probes aim to extend the capability of PET imaging to measure downstream AR transcriptional activ ity. In 2013, one such probe was reported; 89 ZrJ591/PSMA, a radio labelled prostate membrane specific antigen (PSMA) probe, was shown to be inversely related to AR transcriptional activity. 9 In another example, detection of treatmentemergent NEPC driven by cMYC was enhanced with the use of 89 Zrtransferrin, which binds to the transferrin receptor-a direct transcriptional target of cMYC. Preclinical studies have demonstrated the feasibility of this approach, and results of the initial clinical studies are eagerly awaited. 10 Finally, the advantages of MRI and PET imaging of prostate cancer are being merged with the develop ment of clini cal PET-MRI instruments, which will facili tate a morecomprehensive metabolic and functional characterization of both localized and m etastatic disease. 8 In 2013, key advances in the application of imaging were reported across the spectrum of clinical disease states in prostate cancer. Looking forward, prospectively validating imaging technologies, ideally with concur rent integration of emerging genomic and molecular analyses, will help to further define the role of imaging in the clinical care of men with prostate cancer.
